^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Belrapzo (bendamustine RTD)

    i
    Company:
    Eagle Pharma, SymBio Pharma
    Drug class:
    Alkylating agent
    Related drugs:
    Apply
    Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma (SWOG S1608) (NCT03269669)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/23/2018
    Primary completion :
    12/31/2025
    Completion :
    12/31/2025
    CD4
    |
    lenalidomide • doxorubicin hydrochloride • Gazyva (obinutuzumab) • cyclophosphamide • vincristine • prednisone • bendamustine • Ukoniq (umbralisib) • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia (ALLIANCE A041202) (NCT01886872)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    06/07/2024
    Initiation :
    12/09/2013
    Primary completion :
    08/07/2018
    Completion :
    01/30/2025
    CD20 • CD4 • CD5 • FCER2
    |
    Chr t(11;14)
    |
    Imbruvica (ibrutinib) • Rituxan (rituximab) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Mabtas (rituximab biosimilar) • Novex (rituximab biosimilar) • SIBP-02 (rituximab biosimilar)
    Haploidentical Stem Cell Transplant With Prophylactic Natural Killer DLI for Lymphoma, Multiple Myeloma, and CLL (NCT03524235)
    Phase 1
    Noah Merin
    Active, not recruiting
    Last update posted :
    06/04/2024
    Initiation :
    07/18/2018
    Primary completion :
    11/07/2021
    Completion :
    11/01/2031
    MYC • CD20 • HLA-DRB1 • CD4 • HLA-DQB1 • HLA-B
    |
    Chr del(17p) • Chr del(11q) • Chr t(4;14) • Chr t(14;16) • CD20 expression
    |
    Rituxan (rituximab) • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD)
    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma (NCT01286272)
    Phase 2
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    05/17/2024
    Initiation :
    04/08/2011
    Primary completion :
    05/24/2017
    Completion :
    03/07/2025
    BCL2 • CD4
    |
    bortezomib • bendamustine • Arzerra (ofatumumab) • Belrapzo (bendamustine RTD)
    Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma (NCT03696784)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/26/2024
    Initiation :
    03/12/2019
    Primary completion :
    03/22/2027
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous • rimiducid (AP1903)
    Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. (NCT04223765)
    Phase 1
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    11/12/2020
    Primary completion :
    03/22/2028
    Completion :
    03/22/2043
    ALK • BCL2 • BCL6 • IRF4
    |
    ALK positive • BCL6 rearrangement • BCL2 rearrangement
    |
    cyclophosphamide • fludarabine IV • Belrapzo (bendamustine RTD) • cyclophosphamide intravenous
    CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma (NCT04083495)
    Phase 2
    UNC Lineberger Comprehensive Cancer Center
    Recruiting
    Last update posted :
    04/23/2024
    Initiation :
    09/17/2019
    Primary completion :
    02/23/2028
    Completion :
    08/01/2038
    TNFRSF8
    |
    TNFRSF8 expression
    |
    cyclophosphamide • bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11 • cyclophosphamide intravenous
    Sequential Regimen of Bendamustine Followed by Obinutuzumab (GA101), Zanubrutinib (BGB-3111) and Venetoclax (ABT-199) in Patients With Relapsed/Refractory CLL (CLL2-BZAG) (NCT04515238)
    Phase 2
    German CLL Study Group
    Active, not recruiting
    Last update posted :
    03/25/2024
    Initiation :
    10/01/2020
    Primary completion :
    04/01/2025
    Completion :
    03/01/2027
    BCL2 • PLCG2
    |
    Venclexta (venetoclax) • Gazyva (obinutuzumab) • Brukinsa (zanubrutinib) • bendamustine • Belrapzo (bendamustine RTD)
    A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL (ACE-LY-308) (NCT02972840)
    Phase 3
    Acerta Pharma BV
    Active, not recruiting
    Last update posted :
    03/08/2024
    Initiation :
    04/05/2017
    Primary completion :
    10/28/2025
    Completion :
    10/28/2025
    CD20 • CCND1 • PAX5 • CD5
    |
    Chr t(11;14) • CCND1 overexpression • Chr t(11;14)(q13;q32)
    |
    Rituxan (rituximab) • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)
    Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell Lymphoma (NCT03623373)
    Phase 2
    Washington University School of Medicine
    Active, not recruiting
    Last update posted :
    02/13/2024
    Initiation :
    11/29/2018
    Primary completion :
    02/09/2020
    Completion :
    02/05/2025
    CCND1 • CD34
    |
    Chr t(11;14)
    |
    Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Rituxan Hycela (rituximab/hyaluronidase) • Belrapzo (bendamustine RTD)
    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma (NCT04587687)
    Phase 2
    Joseph Tuscano
    Recruiting
    Last update posted :
    01/22/2024
    Initiation :
    12/04/2020
    Primary completion :
    12/01/2024
    Completion :
    05/01/2025
    TNFRSF8 • CD4
    |
    TNFRSF8 positive
    |
    Adcetris (brentuximab vedotin) • bendamustine • Belrapzo (bendamustine RTD)
    A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma (NCT04115631)
    Phase 2
    ECOG-ACRIN Cancer Research Group
    Active, not recruiting
    Last update posted :
    06/22/2023
    Initiation :
    12/13/2019
    Primary completion :
    12/31/2024
    Completion :
    03/31/2025
    CCND1 • CD34
    |
    Chr t(11;14) • CCND1 expression
    |
    Rituxan (rituximab) • cytarabine • Calquence (acalabrutinib) • bendamustine • Truxima (rituximab-abbs) • Belrapzo (bendamustine RTD) • Riabni (rituximab-arrx) • Delito (rituximab biosimilar) • GB241 (rituximab biosimilar) • JHL1101 (rituximab biosimilar) • Novex (rituximab biosimilar) • Starasid (cytarabine ocfosfate)
    Phase 2 Study Evaluating Autologous CD30.CAR-T Cells in Patients With Relapsed/Refractory Hodgkin Lymphoma (CHARIOT) (NCT04268706)
    Phase 2
    Tessa Therapeutics
    Active, not recruiting
    Last update posted :
    04/05/2023
    Initiation :
    02/01/2021
    Primary completion :
    05/01/2025
    Completion :
    03/01/2037
    TNFRSF8
    |
    TNFRSF8 positive
    |
    fludarabine IV • Belrapzo (bendamustine RTD) • TT11
    A Study of Parsaclisib, a PI3Kδ Inhibitor, in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma (CITADEL-310) (NCT04849715)
    Phase 3
    Incyte Corporation
    Withdrawn
    Last update posted :
    04/29/2022
    Initiation :
    03/11/2022
    Primary completion :
    08/15/2030
    Completion :
    07/07/2034
    CD20
    |
    CD20 expression
    |
    Rituxan (rituximab) • bendamustine • parsaclisib (INCB50465) • Belrapzo (bendamustine RTD)
    Compassionate Use Re-Infusion of ATLCAR.CD30 (NCT03914885)
    Phase N/A
    UNC Lineberger Comprehensive Cancer Center
    No Longer Available
    Last update posted :
    12/03/2021
    TNFRSF8
    |
    bendamustine • fludarabine IV • Belrapzo (bendamustine RTD) • TT11